Adverum Biotechnologies Azioni (NASDAQ: ADVM)

Ultime notizie per Adverum Biotechnologies (NASDAQ:ADVM) Azioni

Adverum Biotechnologies

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies Inc

South Bow Corp. ((TSX &amp;, NYSE:<a href="https://www.benzinga.com/stock/SOBO#NYSE">SOBO</a>) has received an unsolicited "mini-tender" offer from TRC Capital Investment Corp. (TRC Capital) to purchase up to 3 million South Bow common shares, or approximately 1.4% of South Bow's outstanding common shares, at a below-market price of C$31.95. South Bow does not endorse TRC Capital's unsolicited offer, has no affiliation with TRC Capital or its offer, and does not recommend or endorse this unsolicited mini-tender offer.
South Bow cautions shareholders that the mini-tender offer has been made at a below-market price for the South Bow common shares. TRC Capital's unsolicited offer price of C$31.95 per share represents a discount of 4.6% to the closing price of the South Bow common shares on the Toronto Stock Exchange and the New York Stock Exchange on Oct. 28, 2024, the last trading day before the mini-tender offer was commenced, and a discount of 7.4% to the closing price on Nov. 1, 2024.

News

Management

SOBO

South Bow Recommends Shareholders Reject TRC Capital's Below-Market "Mini-tender" Offer To Purchase Up To 3M Shares, Or ~1.4% Of South Bow's Outstanding Common Shares, At A Price Of C$31.95 Per Share

As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293294-1&amp;h=2469645923&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fapx-acquisition-corp-i-receives-nasdaq-notice-on-late-filing-of-its-form-10-q-302023280.html%23financial-modal&amp;a=APXI">APXI</a>) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice"). The Company subsequently submitted a plan to regain compliance with the Rule (the "Compliance Plan").
On October 29, 2024, the Company received written notice from the Staff (the "November Notice"), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance.
Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the "Warrant/Unit Delisting"). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the&nbsp;Nasdaq Global Market, other than those contained within the units.

APXI

APXIU

APXIW

APX Acquisition Corp. I Announces Nasdaq Delisting Notification For Warrants And Units

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a Miller's Ale House property for $3.8 million. The property is located in a strong retail corridor in Georgia and is corporate-operated under a long term, net lease with approximately 11 years of term remaining. The transaction was priced at a 7.2% cap rate on rent as of the closing date and exclusive of transaction costs.

FCPT

FCPT Announces Acquisition Of A Miller's Ale House Property For $3.8M

- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology's evorpacept in combination with Jazz Pharmaceuticals' zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS), which will be held in San Antonio, Texas, from December 10-13, 2024.
The Phase 1b/2 clinical trial is a two-part, open-label, multicenter study (<a href="https://www.globenewswire.com/Tracker?data=uP7TgOHeIoBZb8tHT8b8P-5Joh1B-EVwBg4vRKoa2aqEd6K1wLigVjuzGppZ4A3Pcqq8O6QfdpsX2sB5fqmpGS9NQ7SYCSmfS3RFDCelosE=">NCT05027139</a>) that evaluated the potential of evorpacept in combination with zanidatamab as a novel treatment for patients with HER2-expressing breast cancer and other cancers. Data from this study will be summarized in the following poster spotlight presentation:

Biotech

General

ALXO

ALX Oncology Announces Results From Phase 1b/2 Trial Of Evorpacept In Combination With Zanidatamab Will Be Presented At The San Antonio Breast Cancer Symposium 2024

&nbsp;Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4292744-1&amp;h=3267956950&amp;u=https%3A%2F%2Fsabcs.org%2F&amp;a=San+Antonio+Breast+Cancer+Symposium+(SABCS)">San Antonio Breast Cancer Symposium (SABCS)</a> taking place December 10-13 in San Antonio, TX. EMBER-3 is a study in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. The trial is evaluating imlunestrant alone or in combination with Verzenio (abemaciclib; CDK4/6 inhibitor), in patients who were pretreated with endocrine therapy, with or without a CDK4/6 inhibitor.
Lilly will also share results of a real-world analysis of risk of recurrence by nodal status and high-risk features in patients with hormone receptor positive (HR+), HER2- early breast cancer. Additional presentations from investigational mutant selective PI3Ka inhibitor assets include preclinical characterization data for LY4045004, which is expected to enter the clinic in the first half of 2025, and Phase 1a/b clinical data for a predecessor molecule, LOXO-783, which informed the development of LY4045004.

Lilly To Present Results From Phase 3 EMBER-3 Study Of Imlunestrant, An Oral SERD, And Additional Results From Its Breast Cancer Portfolio At The San Antonio Breast Cancer Symposium

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=3420507561&amp;u=https%3A%2F%2Fwww.centene.com%2F&amp;a=Centene+Corporation">Centene Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=1525079035&amp;u=https%3A%2F%2Fwww.buckeyehealthplan.com%2F&amp;a=Buckeye+Health+Plan">Buckeye Health Plan</a>&nbsp;(Buckeye), has been selected by the Ohio Department of Medicaid (ODM) to continue providing Medicare and Medicaid services for dually eligible individuals through a Fully Integrated Dual Eligible Special Needs Plan (FIDE SNP). FIDE SNPs fully integrate care for dually eligible beneficiaries under a single managed care organization, allowing enrollees to receive all of their medical, behavioral and long-term services and supports through one plan.

Centene's Buckeye Health Plan Awarded Contract To Serve Dual Eligible Medicare And Medicaid Members In Ohio

Macro Economic Events

Politics

Economics

STLA

Republican Nominee Donald J. Trump Says 'Tell Stellantis If They Plan On Moving, We're Going To Charge Them A 100% Tariff On Every Car'

Contracts

GRYP

Gryphon Digital Mining & Unit Notified Coinmint Of Their Non-Renewal Of Colocation Mining Services Agreement Dated July 1, 2021

Offerings

PHUN

Phunware Enters Amended And Restated Equity Distribution Agreement; May Offer & Sell Shares For Aggregate Gross Proceeds Up To $171.5M From Time To Time

AIXI

Xiao-I Entered Into Private Placement & Securities Purchase Agreement To Issue, Sell Convertible Promissory Note For $2.1M

LIVN

LivaNova Says CMS Maintains VNS Therapy For DRE At Level 5 APC Under 2025 Medicare Hospital Outpatient Prospective Payment System; Co Will Continue To Pursue Reimbursement Opportunities For VNS Therapy For DRE

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares traded higher Friday as striking employees are expected to vote on a new contract proposal on Monday, Nov. 4. Here&#8217;s<a href="https://www.benzinga.com/markets/equities/24/11/41676667/boeing-sweetens-deal-with-38-wage-hike-12k-bonus-and-more-to-end-7-week-strike-vote-set-for-mond"> what you need to know.</a>
What To Know: According to<a href="https://aviationweek.com/aerospace/manufacturing-supply-chain/boeing-machinists-reach-new-tentative-deal#:~:text=The%20new%20proposed%20deal%2C%20reached,Boeing%20and%20the%20union%20show."> Aviation Daily</a>, the company announced a tentative deal with the International Association of Machinists (IAM), potentially ending a 49-day strike. This union-recommended agreement proposes a 38% wage increase over four years—13% in the first year, followed by 9% in each of the next two years and 7% in the final year. 
Additionally, workers would receive a $12,000 ratification bonus and improved 401(k) contributions. Boeing also committed to locating any new aircraft production in the Puget Sound region of Washington, a key concession for the union.
This deal comes after union members previously rejected two offers, including a 35% wage increase in October. The initial union request included a 40% wage increase and pension restorations, but the new deal focuses on wage hikes and bonuses, while pensions remain unchanged. If approved, Boeing expects production facilities to gradually reopen as early as Nov. 6, with full staffing anticipated over the following weeks.
The strike and production delays have impacted Boeing's suppliers, with some, like Spirit AeroSystems, already implementing employee furloughs. Boeing CEO Kelly Ortberg emphasized the importance of a careful restart process, citing ongoing issues with production stability and meeting FAA safety standards.
What Else: Boeing&#8217;s rating also remains on S&amp;P&#8217;s CreditWatch following a larger-than-anticipated equity issuance, which helps offset projected cash flow deficits through 2025. However, S&amp;P noted Boeing's limited flexibility for further cash flow pressures and cited ongoing strike-related and post-strike operational risks as areas of concern.
BA Price Action: Boeing shares were up 3.5% at $154.59 on Friday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="539" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-1024x539.png" alt="" class="wp-image-626219" style="width:451px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-1024x539.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA.png 1441w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/24/11/41693751/biden-can-blame-boeing-for-massive-jobs-data-miss">Biden Can Blame Boeing For Massive Jobs Data Miss</a></li>
</ul>
Photo via Shutterstock.

Movers

Why Boeing Shares Traded Higher On Friday

WIIM

Sherwin-Williams shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

NVDA

NVIDIA shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

RDZN

Roadzen Files For Mixed Shelf Of Up To $100M

ITRM

Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026

The Symplicity &#x2122; blood pressure procedure offers patients a new adjunct approach to lowering blood pressure&nbsp;
GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122;&nbsp;renal denervation (RDN) catheter, used in the Symplicity&#x2122;&nbsp;blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025

Titan International Files For Offering Of Up To 11.92M Shares By The Selling Stockholders

NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) today announced it has commenced a proposed underwritten public offering in the United States (the "Registered Offering"). Concurrently, the Company has also commenced a private placement (the "Private Offering" and, together with the Registered Offering, the "Offerings").
The Registered Offering consists of common shares and warrants to purchase common shares and is subject to market conditions. There can be no assurance as to whether or when the Registered Offering may be completed, or as to the actual size, pricing or other terms of the Registered Offering. In addition, the Company intends to grant the underwriter a 45-day over-allotment option to purchase up to an additional 15 percent of the number of initial common shares and/or an additional 15 percent of the number of initial warrants offered in the Registered Offering.
The Private Offering consists of common shares and warrants to purchase common shares. There can be no assurance as to whether or when the Private Offering may be completed, or as to the actual size, pricing or other terms of the Private Offering. Completion of the Private Offering is not contingent on completion of the Registered Offering and completion of the Registered Offering is not contingent on the completion of the Private Offering.
Maxim Group LLC is acting as sole book-running manager and underwriter for the Registered Offering.
NioCorp currently intends to use the net proceeds from the Offerings for working capital and general corporate purposes, including to (i) advance its efforts to launch construction of a critical minerals project in Southeast Nebraska (the "Elk Creek Project") and move it to commercial operation and (ii) repay all amounts outstanding under the Company's $2.0 million non-revolving multiple draw credit facility (the "Smith Credit Facility") available pursuant to the Loan Agreement, dated September 11, 2024, by and between the Company and its Chief Executive Officer, President and Executive Chairman, Mark Smith. The Smith Credit Facility will continue to be available to the Company following the close of the Offerings.
The Registered Offering is subject to customary closing conditions.

NioCorp Announces Commencement Of Proposed Underwritten Public Offering Of Common Shares & Warrants; No Size Or Amount Disclosed

CHWY

Chewy shares are trading higher after it was announced that the company will join the S&P MidCap 400 prior to the opening of trading on Wednesday, November 6, 2024.

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report), with a price target of $30...

Adverum Biotechnologies' Ixo-vec Shows Promise in Wet AMD Treatment: Analyst Reiterates Buy Rating and $30 Price Target

RBC Capital analyst Luca Issi maintained a Hold rating on Adverum Biotechnologies (ADVM – Research Report) yesterday and set a price target of $12....

Adverum Biotechnologies (ADVM) Receives a Hold from RBC Capital

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report), with a...

Adverum Biotechnologies (ADVM) Receives a Buy from Oppenheimer

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on ADVM stock, giving a Buy rating on August 13. Graig Suvannavejh ...

Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company's shares closed yesterday at $7.50. According to TipRanks, ...

Truist Financial Issues a Buy Rating on Adverum Biotechnologies (ADVM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adverum Biotechnologies (ADVM – Research Report), Bi...

Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)

Catalyst Watch: Tesla deliveries, Nike earnings, port strike threat and the jobs report

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Chardan Capital analyst Keay Nakae has reiterated their bullish stance on ADVM stock, giving a Buy rating on October 14. Keay Nakae has given his B...

Promising Potential of ADAR RNA Editing Fuels Buy Rating

Oppenheimer Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)

ABBV

ADVM

AFRM

APLS

BMEA

CALM

CAPR

CARM

EDIT

EYPT

FDMT

HRMY

HTLD

IBATF

INFN

LCID

LEVI

NDSN

NNDM

ODFL

PAYX

PLUG

PROK

RGNX

RIVN

SAIA

SAVA

SBUX

SHOP

SITC

SMCI

SOUN

SSNLF

TECX

TSLA

TVTX

WKHS

XPEV

Press Releases

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

Health Care

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Earnings

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Comments

Adverum Biotechnologies

Notizie

Ultime notizie per Adverum Biotechnologies (NASDAQ:ADVM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO